<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="46844">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01824927</url>
  </required_header>
  <id_info>
    <org_study_id>EBCS001</org_study_id>
    <secondary_id>NSFC81200669</secondary_id>
    <nct_id>NCT01824927</nct_id>
  </id_info>
  <brief_title>Pain Expression in the Perioperative Period of Cataract Surgery</brief_title>
  <official_title>Pain Expression in the Perioperative Period of Cataract Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Evidence Based Cataract Study Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Evidence Based Cataract Study Group</source>
  <oversight_info>
    <authority>China: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients having cataract extraction in the second eye under topical anesthesia with
      monitored anesthesia care often report increased pain and awareness relative to the first
      surgery in the fellow eye, despite similar operative and anesthetic conditions. The purpose
      of this study is to investigate the pathogenesis of this phenomenon.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2013</start_date>
  <primary_completion_date type="Anticipated">May 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care</study_design>
  <primary_outcome>
    <measure>Post operative pain level</measure>
    <time_frame>3 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Post operative pain level recorded on a VAS (0-10) at rest for the first three days after cataract surgery.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Cataract</condition>
  <condition>Surgery</condition>
  <condition>Eye Pain</condition>
  <arm_group>
    <arm_group_label>First eye (FE)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Phacoemulsification cataract extraction surgery of first eye</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Second eye (SE)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Phacoemulsification cataract extraction surgery of second eye</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Steroids eye drops</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dexamethasone eye drop, 1 drop, qid, for 3 days before surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>First eye (FE)</intervention_name>
    <description>Phacoemulsification cataract extraction surgery</description>
    <arm_group_label>First eye (FE)</arm_group_label>
    <arm_group_label>Steroids eye drops</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Second eye (SE)</intervention_name>
    <description>Phacoemulsification cataract extraction surgery</description>
    <arm_group_label>Second eye (SE)</arm_group_label>
    <arm_group_label>Steroids eye drops</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Steroids eye drops</intervention_name>
    <description>Use steroids eye drops to decrease the pain.</description>
    <arm_group_label>First eye (FE)</arm_group_label>
    <arm_group_label>Second eye (SE)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age-related cataract patients aged 50 years or older able to give informed consent
             undergoing cataract surgery;

          -  Pupil dilation ≧7 mm after mydrisis;

          -  VA prognosis ≧6/12

        Exclusion Criteria:

          -  Unable to give informed consent;

          -  Patients with history of ocular pathology or diabetic retinopathy;

          -  Patients with traumatic, subluxated and posterior polar cataract;

          -  Patients had other ocular surgery (not cataract surgery) in the past 6 months;

          -  Patients with significant intra-operative complications
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Peng ZHOU, M.D.</last_name>
    <phone>+86-18801871108</phone>
    <email>drzhoupeng@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Eye and ENT Hospital of Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200031</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peng Zhou, M.D.</last_name>
      <phone>+86-18801871108</phone>
      <email>drzhoupeng@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Peng Zhou, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xiang-Jia Zhu, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ke-Ke Zhang, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hong-Fei Ye, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yi Lu, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <lastchanged_date>April 4, 2013</lastchanged_date>
  <firstreceived_date>April 2, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Evidence Based Cataract Study Group</investigator_affiliation>
    <investigator_full_name>Peng ZHOU</investigator_full_name>
    <investigator_title>Secretary of EBCS Group</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cataract</mesh_term>
    <mesh_term>Eye Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Tetrahydrozoline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
